Bayer stock at EUR 52.02, up 0.35% before Xetra open
Published on 11/04/2026 at 08:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSEarnings Lift 2026 Outlook
- Bayer reported third-quarter sales of EUR 10.053 billion, up 4.1 percent on a reported basis.
- EBITDA before special items rose 6.9 percent to EUR 1.615 billion.
- Pharmaceuticals drove growth, while Crop Science faced lower sales and earnings after currency and portfolio adjustments.
- Free cash flow fell to negative EUR 293 million, partly because of settlement payments.
Bayer stock traded at EUR 52.02 on Lang & Schwarz at 08:19 CET on Wednesday, November 4, 2026, 0.35 percent above the Xetra close of Tuesday, November 3, 2026 at EUR 51.84. The real-time quote of Bayer stock reflects the premarket indication before the Xetra session.
Quarterly Growth Supports Guidance
Bayer said in its third-quarter results release published on Tuesday that group sales reached EUR 10.053 billion, increasing 4.1 percent on a reported basis and 1.9 percent after currency and portfolio adjustments. EBITDA before special items rose 6.9 percent to EUR 1.615 billion.
Pharmaceuticals provided the main operating lift and entered what Bayer described as a new growth cycle. Crop Science recorded lower sales and earnings after currency and portfolio adjustments, while Consumer Health sales remained at the prior-year level and earnings declined. Core earnings per share fell to EUR 0.31, affected by non-cash charges linked to interest-rate changes.
Net income was negative EUR 672 million, including impairment losses in Pharmaceuticals and Consumer Health. Free cash flow fell to negative EUR 293 million, partly because of settlement payments. Bayer also reported net financial debt of EUR 31.083 billion and improved several full-year targets, including the outlook for Pharmaceuticals margin, group EBITDA before special items and free cash flow.
The DAX provides the broader German market backdrop for Bayer stock.
More news and analyses on Bayer stock remain focused on the earnings outlook, pharmaceuticals growth and litigation-related cash costs.
